Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 3Phase 4 1Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 3Withdrawn 1

Sponsor Class

INDUSTRY 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Urinary Bladder Neoplasms 12Non-Muscle Invasive Bladder Neoplasms 4Recurrence 2Lung Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Mitomycin 12Gemcitabine 9BCG Vaccine 4apaziquone 3Epirubicin 3erdafitinib 2durvalumab 2dodecyl maltoside 2VB4-845 2Docetaxel 2viscum album peptide 1valrubicin 1pirarubicin 1hydroxycamptothecinum 1Transurethral Resection of Bladder 1Therapeutic Uses 1Standard of Care 1Saline Solution 1Radiotherapy 1Polysorbates 1Maintenance 1Magnetic Resonance Spectroscopy 1Injections 1Cystoscopy 15-aminolevulinic acid hexyl ester 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Non-Muscle Invasive Bladder Neoplasms × BCG Vaccine × Clear all
NCT05538663 2026-05-05

BRIDGE

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
870 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT03528694 2026-04-14

POTOMAC

AstraZeneca

Phase 3 Active not recruiting
1,018 enrolled 1 FDA
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04165317 2026-01-22

CREST

Pfizer

Phase 3 Active not recruiting
1,068 enrolled 20 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT01284205 2014-08-29

First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC

Bioniche Life Sciences Inc.

Phase 3 Withdrawn
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡